Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (Nasdaq:XENE) announced significant efficacy results from the Phase 2b X-TOLE trial of XEN1101, showing rapid reduction in focal onset seizures within one week across all doses. The median percent reduction was 55.4% for the 25 mg dose (p<0.001), with continued effectiveness in the open-label extension (OLE) phase, exceeding 70% reduction at 3 months and 80% at 12 months. The company plans to extend the OLE from three to five years. XEN1101 has shown a favorable safety profile, aligning with other anti-seizure medications.
Xenon Pharmaceuticals announced plans to initiate the Phase 3 clinical program for XEN1101 targeting focal onset seizures in the second half of 2022. Following a successful End-of-Phase 2 meeting with the FDA, Xenon expects to submit a New Drug Application (NDA) post-completion of the X-TOLE2 trial, built on strong Phase 2b data indicating significant seizure reduction. An additional Phase 3 trial, X-ACKT, for primary generalized tonic clonic seizures is also set to begin. Approximately 360 patients will partake in pivotal trials assessing the efficacy and safety of XEN1101.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company specializing in neurology, will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. Ian Mortimer, President and CEO, will present on June 8 at 2:30 pm Eastern Time. A live webcast will be available on the company’s website, with archived recordings to follow. Xenon focuses on developing therapies for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its financial results for Q1 2022, highlighting key developments in its clinical programs. The company is progressing towards an end-of-Phase 2 meeting with the FDA regarding XEN1101 for epilepsy, with Phase 3 initiation expected in H2 2022. Xenon has also initiated a Phase 2 trial for XEN1101 in major depressive disorder (MDD). Financially, the company recorded revenues of $8.8 million, up from $4.4 million YoY, but incurred a net loss of $19.7 million due to increased operational costs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2022 financial results on May 10, 2022, after U.S. market close. The company, focused on developing therapeutics for neurological disorders, particularly epilepsy, will host a conference call at 4:30 PM ET to discuss the results. Participants can join using the provided dial-in numbers, with international access available. The event will also be streamed live on the company's investor website. Further information about their ongoing pipeline and developments can be found online.
Xenon Pharmaceuticals (NASDAQ:XENE) has announced the initiation of the Phase 2 'X-NOVA' clinical trial to assess the efficacy and safety of XEN1101 in treating Major Depressive Disorder (MDD). The study will involve approximately 150 subjects and include placebo controls. The trial aims to evaluate the impact of XEN1101 on depressive and anhedonia symptoms over six weeks. Promising pre-clinical data and previous studies support the potential of XEN1101 as a novel treatment approach for MDD. Topline results are expected in 2023.
Xenon Pharmaceuticals, focused on neurology, announced its participation in key investor conferences. The Jefferies Biotech on the Bay Summit is scheduled for April 26-27, 2022, in Miami, FL, featuring one-on-one meetings. The Bloom Burton & Co. Healthcare Investor Conference will take place on May 2-3, 2022, in Toronto, with a presentation on May 3 at 11:30 am ET. Lastly, the RBC Capital Markets Global Healthcare Conference will occur on May 17-18, 2022, in New York, highlighted by a fireside chat on May 18 at 11:00 am ET. For further details, visit Xenon's investor page.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced participation in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference on April 11, 2022. The fireside chat will occur from 10:15-10:55 am Eastern Time, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO. Recordings of the presentation will be available post-event on their website. The company is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) announced participation in the Stifel 2022 CNS Days virtual conference on March 29, 2022. Management will engage in one-on-one investor meetings and a fireside chat from 11:00-11:25 am Eastern Time. Presenters include Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer.
The company focuses on developing innovative therapeutics for neurological disorders and has a pipeline aimed at addressing high unmet medical needs, particularly in epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its 2021 financial results, highlighting significant advancements in clinical trials, particularly for XEN1101, a treatment for epilepsy and major depressive disorder. The Phase 2b X-TOLE trial showed strong efficacy, prompting plans for a Phase 3 development in 2022. Financially, total revenue dropped to $18.4 million with a net loss of $78.9 million, attributed to increased R&D and administrative expenses. Xenon maintains a robust cash position of $551.8 million, sufficient to fund operations into at least 2024.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
